08:14 AM EDT, 03/20/2024 (MT Newswires) -- MindBio Therapeutics Corp. (MBIO.CN) earlier on Wednesday said first dosing has begun in a Phase 2B randomised controlled clinical trial microdosing MB22001 in patients with Major Depressive Disorder.

The company has secured regulatory and ministerial approvals for MB22001 to be self-administered by participants in the community and at home. In this trial, patients with major depressive disorder (MDD) will undertake an eight-week regimen of MindBio's lead candidate drug, MB22001, a proprietary titratable and self-administered form of Lysergic Acid Diethylamide (LSD) designed for take-home use.

In this trial (n=90) half the participants will take an active placebo and the other half will take MB22001. After the trial, both placebo and drug group participants will be invited to participate in an eight week open-label extension to ensure the placebo group has the opportunity to experience treatment with MB22001 resulting in potentially 16 weeks of data being collected from every patient.